Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: Approved therapies and emerging candidates

Divyanshu Dubey, Bernd C. Kieseier, Hans Peter Hartung, Bernhard Hemmer, William A. Miller-Little, Olaf Stuve

Research output: Contribution to journalReview article

13 Scopus citations

Abstract

Therapeutic monoclonal antibodies (mAbs) are a relatively novel class of drugs that has substantially advanced immunotherapy for patients with multiple sclerosis. The advantage of these agents is that they bind specifically and exclusively to predetermined proteins or cells. Natalizumab was the first mAb in neurology to obtain approval. It is also considered one of the most potent options for annualized relapse rate reduction among available therapeutic options. Alemtuzumab is currently also approved in several countries. Several mAbs have been tested in clinical studies in multiple sclerosis. Here, we review the history of drug development of therapeutic mAbs and their classification. Furthermore, we outline the putative mechanisms of action, clinical evidence and safety of approved mAbs and those in different stages of clinical development in multiple sclerosis and neuromyelitis optica.

Original languageEnglish (US)
Pages (from-to)93-108
Number of pages16
JournalExpert review of clinical immunology
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2014

Keywords

  • MS
  • monoclonal antibodies
  • multiple sclerosis
  • pharmacology
  • therapies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: Approved therapies and emerging candidates'. Together they form a unique fingerprint.

  • Cite this